Comparison
Retatrutide vs Tirzepatide
Triple agonist vs dual agonist — the next frontier in weight loss.
Reviewed by Dr. Sarah Mitchell, PharmD
Receptors
GLP-1 + GIP + Glucagon (triple)
GLP-1 + GIP (dual)
Weight Loss
~24% in Phase 2
~20–22% in Phase 3
Liver Fat
~90% resolution of NAFLD
Significant reduction
FDA Status
Phase 3 trials (not yet approved)
FDA approved
Thermogenesis
Yes (glucagon component)
Minimal
Dosing
Weekly injection
Weekly injection
Manufacturer
Eli Lilly
Eli Lilly
Availability
Clinical trials only
Available by prescription
Our Verdict
Retatrutide achieves greater weight loss (24% vs 22%) by adding glucagon receptor activation for thermogenesis and liver fat clearing. However, tirzepatide is FDA-approved now while retatrutide is still in Phase 3 trials. Retatrutide may become the new gold standard upon approval.